Biological E Taps Takeda Tech For Affordable Combo Vaccines
Takeda is to transfer selected vaccine technologies to an Indian manufacturer to enable the production of affordable combination vaccines for lower income countries, although likely volumes and prices remain unclear for now.
You may also be interested in...
Will Takeda take a less measured approach in India, where Shire brings it a significant on-market portfolio? Scrip outlines the current shape of things in the promising but complex emerging market as the two companies head towards combining forces globally.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
Newly published details of interim clinical data for Takeda's candidate vaccine for dengue show activity across all serotypes that seems to bode well for an ongoing Phase III trial with the potential rival to the only currently available vaccine, Sanofi's Dengvaxia.